A b s t r a c t
Hemoglobin (Hb) A 1c , the major form of glycated hemoglobin, is the result of the nonenzymatic glycation of the N-terminal valine residues of the β chain of HbA. HbA 1c has been shown to be a key biomarker whose measurement provides the most important medium to long-term time-averaged glycemic status. Its relationship with the clinical outcome and complications of diabetes mellitus has been convincingly demonstrated for both type I and type II subjects in 2 major clinical trials. 1, 2 The recently implemented consensus statement on worldwide standardization 3 and the International Federation of Clinical Chemistry (IFCC) reference method for HbA 1c measurement 4 have contributed substantially to improving the quality of HbA 1c measurements. Expanding the role of this hemoglobin fraction from monitoring to screening and diagnosis of diabetes 5 leads to a greater use for this test.
Various methods have been used for the measurement of glycohemoglobins. 6 Because of their automation and precision, the high-performance liquid chromatography (HPLC) methods have been favored, but recently capillary electrophoresis has been developed and adapted to the analysis of HbA 1c .
The CAPILLARYS HbA 1c kit (Sebia, Lisses, France) is designed for the separation and quantification of the HbA 1c fraction of hemoglobin in human blood by means of capillary electrophoresis in an alkaline buffer with the CAPILLARYS 2 Flex Piercing instrument (Sebia). By using alkaline pH buffer, normal and abnormal (or variants) levels of hemoglobin are detected in the following order, from cathode to anode: A2/C, E, S, D, F, A0, other hemoglobins (including minor HbA 1 ) and then A 1c .
Hemoglobinopathies and thalassemias are among the most common genetic disorders worldwide. 7 Thus, hemoglobin variants can be a serious issue for the accuracy of HbA 1c quantification in the course of routine control of diabetes. Thalassemia is prevalent in the Mediterranean basin and in Southeast Asia, where it represents a major public health problem. However, nonendemic countries are also involved in thalassemia-related problems as a result of the migration of groups with a high frequency of thalassemic mutations. 8 HbA 2 quantification plays a key role in screening programs for thalassemia: its decrease might reveal α-thalassemia and its increase β-thalassemia. 9 The analytic performance of the CAPILLARYS 2 Flex Piercing instrument was evaluated to verify the quality of HbA 1c quantification, based on the criteria established in the recently published documents of consensus on HbA 1c . Special attention was paid to the influence of the most frequent analytic interferences: labile HbA 1c (LA 1c ), carbamylated hemoglobin (cHb), acetylated hemoglobin (AcHb), and fetal hemoglobin (HbF); the ability of the system to quantify HbA 1c in the presence of the most frequent hemoglobin variants was also evaluated. The quantification of HbA 2 using both the CAPILLARYS hemoglobin program and the CAP-ILLARYS HbA 1c program was compared to assess the ability of the HbA 1c program to report a reliable HbA 2 value for the detection of β-thalassemia.
Materials and Methods
The CAPILLARYS 2 Flex Piercing analyzer as well as the reagents (HbA 1c kit, reference no. 2015) used for this evaluation were provided by Sebia and used according to the manufacturer's instructions. HbA 1c values are reported in percentages; a master equation can be used to calculate values in millimoles per mole. 3 
CAPILLARYS 2 Flex Piercing Analyzer
The CAPILLARYS 2 Flex Piercing is a multiassay fully automated analyzer that allows the analysis of whole blood samples directly from primary capped tubes. The CAPIL-LARYS 2 Flex Piercing instrument has 8 silica capillaries functioning in parallel, allowing 8 simultaneous analyses for HbA 1c quantification from whole blood samples. The CAPIL-LARYS HbA 1c kit (migration buffer, hemolysing solution, wash solution, and dilution segments, reference no. 2015), controls (levels 1 and 2, reference no. 4774), and calibrators (levels 1 and 2, reference no. 4755) were used. The assay was performed on the hemolysate of whole blood samples collected in tubes containing ethylenediaminetetraacetic acid (EDTA) as anticoagulant. A sample dilution with hemolysing solution was automatically prepared and injected by aspiration at the anodic end of the capillary. A high-voltage protein separation was then performed and hemoglobin directly detected at the cathodic end of the capillary at 415 nm, which is the specific absorbance wavelength for hemoglobin. 
Samples and Controls
Blood specimens were obtained from patients whose diabetic control or hemoglobinopathy were being assessed routinely and were used in this study according to the hospital's ethics guidelines. Whole blood samples were obtained in the course of routine analysis and collected in EDTA anticoagulant tubes (Vacutainer Becton-Dickinson, Rutherford, NJ). Quality control materials used throughout the evaluations were provided by Sebia (levels 1 and 2, reference no. 4774).
Linearity Study
The linearity of the method was evaluated by measuring HbA 1c in serial dilutions of 2 blood samples with high (14.6%) and normal (5.1%) values, containing the same total hemoglobin concentration.
Precision Study
Intra-assay precision was determined by 5 quantifications from the same sample for 3 levels of HbA 1c (5.2%, 7.2%, and 10.9%) within the same series. Interassay precision was determined by 5 quantifications of 8 samples with different levels of HbA 1c .
Correlation Study
HbA 1c results obtained with the CAPILLARYS 2 Flex Piercing analyzer were compared with the results obtained with the ion-exchange HPLC system used routinely in the laboratory for HbA 1c assay (Menarini/Arkray ADAMS A1c HA-8160, Menarini Diagnostics, Firenze, Italy). The study was performed according to guideline EP9 of the Clinical Laboratory Standards Institute; 107 samples without hemoglobin variants were analyzed in duplicate.
Interferences
The interference of cHb was performed by incubating a pooled blood sample (HbA 1c , 5.0%) with increasing concentrations of a sodium cyanide solution (≤10 mmol/L). The samples were incubated for 2 hours at 37ºC, and then analyzed.
The interference of LA 1c was performed by incubating a pooled blood sample (HbA 1c , 5.2%) with increasing concentrations of a glucose solution (≤1,000 mg/dL [≤55.5 mmol/L]). The samples were incubated for 2 hours at 37º C, and then analyzed.
The interference of AcHb was performed by incubating a pooled blood sample (HbA 1c , 5.0%) with increasing concentrations of an acetaldehyde solution (2-10 mol/L). The samples were incubated for 2 hours at 37ºC, and then analyzed.
The effect of HbF concentration was investigated by mixing blood samples (with known HbA 1c levels) with umbilical cord blood to obtain HbF levels up to 15% (HbF values were determined using the CAPILLARYS 2 Flex Piercing hemoglobin method).
The potential interference of lipemia was investigated by overloading pooled blood samples (HbA 1c , 
Effect of Hemoglobin Concentration
The effect of varying hemoglobin concentrations on electrophoretic quantification was tested by mixing RBCs of a patient with a known HbA 1c (7.1%) with their own plasma at different ratios. The range of hemoglobin concentrations studied was between 2 g/dL (20 g/L) and 19.5 g/dL (195 g/L).
HbA 2 Quantification With the HbA 1c Program
The HbA 2 concentration was tested with the HbA 1c program on CAPILLARYS 2 Flex Piercing for 279 normal individuals and 64 β-thalassemia carriers. An independent sample t test was performed to detect statistical differences between both groups. A P value less than .05 was considered statistically significant. Receiver operating curve (ROC) analysis was applied to calculate the best cutoff to discriminate noncarriers vs carriers of the β-thalassemia trait.
The HbA 2 level was quantified in parallel using the hemoglobin program on CAPILLARYS 2 Flex Piercing for 60 normal individuals and 64 β-thalassemia carriers. Both results were plotted and the correlation between the 2 programs was studied with the Passing-Bablok regression. SPSS version 19.0 for Windows statistical software package (SPSS, Chicago, IL) was used for statistical analysis of the results.
Results

Analytic Performance of the HbA 1c Quantification on CAPILLARYS 2 Flex Piercing
A typical electrophoretogram exhibits 3 peaks that correspond to HbA 0 , HbA 1c , and HbA 2 , and an additional fraction identified as "other HbA" ❚Figure 1A❚. All peaks are well separated, with a good return to baseline between them. Any modification of this profile, usually because of the presence of a hemoglobin variant, is indicated by the software as "atypical profile" with a special color code, thus allowing the rapid and easy identification of samples with hemoglobin variants.
The linearity of the method in the range of HbA 1c values tested (5.1%-14.6%) was excellent, with a correlation coefficient of 0.9974 ❚Figure 1B❚.
The intraassay coefficients of variation (CVs) were calculated for 3 HbA 1c levels and remained less than 1.4% ( The Bland-Altman plot highlighted the fact that some values obtained with the Menarini analyzer were higher in the range of 12.0% to 16.0%, compared with CAPILLARYS 2 Flex Piercing ❚Figure 1D❚. This representation also showed that 7.5% of values were discordant (differences outside the range, mean ± 2 SD).
Effect of Common Interferents on HbA 1c Quantification With CAPILLARYS 2 Flex Piercing
The quantification of HbA 1c with the CAPILLARYS 2 Flex Piercing analyzer was not influenced by the presence of LA 1c or cHb in the range tested (≤5.1% of LA 1c and 6.7% for cHb, as quantified with HPLC using the Menarini/Arkray ADAMS A 1c HA-8160) ❚Figure 2A❚ and ❚Figure 2B❚. With both interferences, the pattern was unchanged, suggesting that the LA 1c and cHb comigrate with the HbA 0 peak (data not shown). The influence of the most frequent hemoglobinopathies HbS, HbC, HbD, HbE, HbLepore, or β-thalassemia also was evaluated. These profiles were labeled "atypical" because of the presence of additional peaks. The hemoglobin variants were well separated from HbA 1c and HbA 0 peaks, and did not interfere with HbA 1c peak quantification. HbA 1c measurement was not affected by the variation of total hemoglobin concentration in the range of 2. The results in β-thalassemia carriers (3.1%-6.3%) were statistically different from the noncarriers (1.4%-2.8%) (P < .001). ROC analysis rendered an area under curve of 1.0 (95% confidence interval, 0.988-1.00), with a cutoff value higher than 2.8% and sensitivity and specificity of 100%.
Correlation Between HbA 2 Quantification With the HbA 1c Program and the Hemoglobin Program
Finally, the HbA 2 percentages obtained with both programs were plotted for 30 noncarriers and 64 carriers of the β-thalassemia trait with a range of 1.8% to 6.3% ❚Figure 4❚. The results clearly showed a very good correlation between both techniques, with a coefficient of correlation of 0.9766 (P < .001). These data suggest that, in addition to an accurate ❚Figure 3❚ The percentage of the HbA 2 was analyzed with the HbA 1c program on CAPILLARYS 2 Flex Piercing for a non-β-thalassemic population (279 samples). A, The frequency of HbA 2 (in percentage) is represented with a minimum and maximum HbA 2 of 1.4% and 2.8% respectively. Samples of 64 β-thalassemia carriers were analyzed for HbA 2 using the same program. B, The frequency of HbA 2 is represented (in percentage), in which the lowest value obtained was 3.1% and the highest 6.3%. C, The box-and-whisker plot shows the frequency of HbA 2 in patients with thalassemia and healthy subjects. D, The receiver operating characteristics curve shows the sensitivity and specificity, with an area under the curve of 1.00 and cutoff value higher than 2.8%. The current experiments show that HbA 1c levels had no significant increase after incubation with glucose, suggesting that the tested method is specific for the stable HbA 1c fraction. In the same samples, after incubation with glucose, the LA 1c fraction had a fourfold increase over the basal level (1.4% to 5.3% in the sample with a glucose level of 1,000 mg/dL [55.5 mmol/L]) while HbA 1c quantification remained stable at 5.1%.
Technological advances have enabled modern analyzers with high-resolution capabilities to handle these potentially interfering components. The presence of uremia in patients whose long-term glycemic status is being assessed is not an uncommon finding in patients whose renal function has deteriorated. Yet another potential interference with some, though not all, HbA 1c methods, is that cHb elutes next to the HbA 1c fraction. [15] [16] [17] In vitro experiments using sodium cyanate showed that the cHb fraction was increased up to 6.7%, while the HbA 1c fractions were stable within ± 0.3% of the initial sample, so the HbA 1c results remain reliable.
In the same way, this study showed the absence of interference of AcHb on HbA 1c measurement with CAPILLARYS Flex Piercing. This common modified hemoglobin found in pregnant women, alcoholic patients, or even patients being interference-free measurement of HbA 1c , compared with the hemoglobin program, the HbA 1c program on CAPILLARYS 2 Flex Piercing is suitable for detecting β-thalassemia with a reliable measurement of the HbA 2 .
Discussion
HbA 1c is a highly requested test in the clinical laboratory, which requires efficiency in its performance. Complete automation, high result turnaround times, instrument robustness, and low costs are prerequisites for selecting a suitable analyzer. Efforts of manufacturers contributed to improvements in analyzers, creating systems with high throughput.
Capillary electrophoresis is widely used in the clinical laboratory for the separation and quantification of protein fractions, serum proteins, hemoglobin fractions for the diagnosis of hemoglobinopathies, and HbA 2 /HbF quantification. Technological development has allowed Sebia to adapt its CAPILLARYS 2 Flex Piercing instrument for the analysis of HbA 1c . On the other hand, therapeutic strategies rely on reproducible and unbiased methods. These analytical and clinical requirements become even more important now, when HbA 1c is on the threshold of becoming applicable for screening and diagnosis of diabetes. 5 A high level of reproducibility of HbA 1c measurement is essential for providing laboratory support for diabetes monitoring. Changes in results obtained between patient visits to the physician must reflect the pathology of the disease and its response to treatment rather than an analytic uncertainty. Biological variation generally has dictated the desirable targets for the performance of laboratory analysis. 10 However, it has been shown that the situation in persons with diabetes is more complex, being affected by both clinical control and sampling intervals; a practical working CV of 2% has been proposed for analytic reproducibility in long-term monitoring. 11 In the current study, the CAPILLARYS 2 Flex Piercing analyzer achieved this target and had excellent reproducibility (CVs <1.4%), far below the stringent requirement of 2%. 12 Hemoglobin concentration had no significant effect on HbA 1c . The results were reliable within a wide range of total hemoglobin values (2.1-19.5 g/dL Although an HbA 2 fraction higher than 2.8% strongly suggests the presence of the β-thalassemia trait, further studies need to be conducted to prove its precision, 23 according to the recently published recommendations on HbA 2 . 24 In summary, given the short time for analysis and the high throughput, this is a suitable system for diabetes control in patients and for detecting hemoglobinopathies in laboratories with high workflow. 
